Helicobacter Infection
Conditions
Keywords
Helicobacter pylori, Personalized therapy, antimicrobial susceptibility, rescue therapy, culture
Brief summary
As increasing the antibiotics resistance, the effectiveness of traditional Helicobacter pylori (H. pylori) therapies has been declined coincidently. In this study, the investigators evaluated the efficacy of H. pylori eradication between a personalized therapy for H. pylori infection based on the results of antibiotics resistance by using H. pylori culture and minimal inhibitory concentration (MIC) and the traditional 2nd rescue regimens, and the investigators analyzed the prevalence of the antibiotic resistance after 1st eradication of H. pylori in the tailored therapy group.
Detailed description
The patients who had shown the evidence of persistent H. pylori infection after the 1st eradication were enrolled for this study. After giving the informed consent about the method and efficacy (ITT and PP analysis) of the traditional 2nd rescue therapy and the tailored therapy for H. pylori infection based on culture and MIC, the patients were classified into the three regimen group under the patient's agreement and underwent 2nd eradication \[14 days bismuth-based quadruple therapy (Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d.), 14 days moxifloxacin-containing triple therapy (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.), or tailored therapy based on H. pylori culture and MIC (select the 2nd rescue regimen between 14 days of bismuth-based quadruple therapy or 14 days moxifloxacin-containing triple therapy according to antibiotics susceptibility)\].This study was analyzed the success of eradication for enrolled participants retrospectively, however the patients were enrolled prospectively based on previous study about antimicrobial susceptibility test for H. pylori in Korea.
Interventions
PROCEDUREH. pylori culture and antimicrobial susceptibility test
Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute \[amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC \> 1.0 μ g / ml; metronidazole (MET), MIC \> 8 μ g / ml; tetracycline (TC), MIC \> 4 μ g / ml; and moxifloxacin (MOX), MIC \> 1 μ g / ml).
DRUG14 day PBMT group
Rescue therapy using 14 day PBMT regimen \[Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d\]
DRUG14 day MEA group
Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)
Sponsors
Seoul National University Bundang Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* The patients who proved a failure of 1st eradication of H. pylori with Proton pump inhibitor based triple therapy (PPI bid + amoxacillin 1g b.i.d + Clarithromycin 500 mg b.i.d) or sequential therapy (initial 5-day therapy with a combination of PPI b.i.d and amoxicillin 1g b.i.d, followed by 5 days of PPI b.i.d., clarithromycin 500mg b.i.d., and metronidazole 500mg t.i.d) following three methods 1. positive rapid urease test (CLOtest) 2. histologic evidence of H. pylori by modified Giemsa staining 3. positive 13C-Urea breath test * Male and female Korean Adult (Aged ≥ 18 years)
Exclusion criteria
* Patients who received two or more eradication therapy for H. pylori infection * H. pylori eradication failure because of poor compliance * the administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks * Advanced gastric cancer or other malignancy * Abnormal liver function or liver cirrhosis * Abnormal renal function or chronic kidney disease * Other severe concurrent diseases * Previous allergic reactions to the study drugs * Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants in Each Arm/Group With Successful H. Pylori Eradication | 6 weeks after completion of eradication | the efficacy of H. pylori eradication between a personalized therapy for H. pylori infection based on the results of antibiotics resistance by using H. pylori culture and minimal inhibitory concentration (MIC) and the traditional 2nd rescue regimens. The eradication rate was evaluated by intention to treat (ITT) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants in Each Arm/Group With Successful H. Pylori Eradication | 6 weeks after completion of eradication | the efficacy of H. pylori eradication between a personalized therapy for H. pylori infection based on the results of antibiotics resistance by using H. pylori culture and minimal inhibitory concentration (MIC) and the traditional 2nd rescue regimens. The eradication rate was evaluated by per-protocol analysis (PP) |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 14 Day PBMT Group Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
14 day PBMT group: Rescue therapy using 14 day PBMT regimen \[Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d\] | 89 |
| 14 Day MEA Group PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.
14 day MEA group: Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.) | 89 |
| 14 Day Tailored Therapy Group based on H. pylori culture and MIC, select the 2nd rescue regimen between 14 days of bismuth-based quadruple therapy or 14 days moxifloxacin-containing triple therapy according to antibiotics susceptibility. | 41 |
| Total | 219 |
Baseline characteristics
| Characteristic | 14 Day MEA Group | 14 Day Tailored Therapy Group | Total | 14 Day PBMT Group |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 37 Participants | 14 Participants | 91 Participants | 40 Participants |
| Age, Categorical Between 18 and 65 years | 52 Participants | 27 Participants | 128 Participants | 49 Participants |
| Age, Continuous | 59.2 years | 54.5 years | 54.5 years | 55.7 years |
| Region of Enrollment Korea, Republic of | 89 participants | 41 participants | 219 participants | 89 participants |
| Sex: Female, Male Female | 53 Participants | 25 Participants | 121 Participants | 43 Participants |
| Sex: Female, Male Male | 36 Participants | 16 Participants | 98 Participants | 46 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 84 | 0 / 87 | 0 / 37 |
| serious Total, serious adverse events | 0 / 84 | 0 / 87 | 0 / 37 |
Outcome results
Primary
Number of Participants in Each Arm/Group With Successful H. Pylori Eradication
the efficacy of H. pylori eradication between a personalized therapy for H. pylori infection based on the results of antibiotics resistance by using H. pylori culture and minimal inhibitory concentration (MIC) and the traditional 2nd rescue regimens. The eradication rate was evaluated by intention to treat (ITT)
Time frame: 6 weeks after completion of eradication
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 14 Day PBMT Group | Number of Participants in Each Arm/Group With Successful H. Pylori Eradication | 67 participants |
| 14 Day MEA Group | Number of Participants in Each Arm/Group With Successful H. Pylori Eradication | 63 participants |
| 14 Day Tailored Therapy Group | Number of Participants in Each Arm/Group With Successful H. Pylori Eradication | 36 participants |
Secondary
Number of Participants in Each Arm/Group With Successful H. Pylori Eradication
the efficacy of H. pylori eradication between a personalized therapy for H. pylori infection based on the results of antibiotics resistance by using H. pylori culture and minimal inhibitory concentration (MIC) and the traditional 2nd rescue regimens. The eradication rate was evaluated by per-protocol analysis (PP)
Time frame: 6 weeks after completion of eradication
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 14 Day PBMT Group | Number of Participants in Each Arm/Group With Successful H. Pylori Eradication | 67 participants |
| 14 Day MEA Group | Number of Participants in Each Arm/Group With Successful H. Pylori Eradication | 63 participants |
| 14 Day Tailored Therapy Group | Number of Participants in Each Arm/Group With Successful H. Pylori Eradication | 37 participants |